Age: 18.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hemiparesis, Magnetic resonance imaging, Neurological symptom, Ultrasound Doppler, Vision blurred
Clinical narrative: Vision was affected; Weakness on the entire right side of body for 20 minutes; Stroke; This spontaneous case was reported by a consumer and describes the occurrence of HEMIPARESIS (Weakness on the entire right side of body for 20 minutes) and CEREBROVASCULAR ACCIDENT (Stroke) in an 18-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033H21A and 032H21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 29-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Jun-2022, the patient experienced HEMIPARESIS (Weakness on the entire right side of body for 20 minutes) (seriousness criterion medically significant) and CEREBROVASCULAR ACCIDENT (Stroke) (seriousness criterion medically significant). On 15-Jul-2022, the patient experienced VISUAL IMPAIRMENT (Vision was affected). On 15-Jun-2022, HEMIPARESIS (Weakness on the entire right side of body for 20 minutes) had resolved. At the time of the report, CEREBROVASCULAR ACCIDENT (Stroke) and VISUAL IMPAIRMENT (Vision was affected) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Jun-2022, Magnetic resonance imaging: had a Stroke.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication details were reported.  On 15-Jun-2022, the patient had weakness on the entire right side of body for 20 minutes. It affected his speech, gate, cognitive abilities and vision. Patient spent 5 hours at the emergency room. The next day the PCP ordered an MRI and stated that the patient had a Stroke on 15-Jun-2022. Since then, the patient had been seeing a cardiologist and a Neurologist. They were still testing him. The patient's mother stated that from 29-Dec-2021 to 14-Jun-2022, patient did not have any adverse events. The patient was totally healthy prior to vaccination and was not on any type of Medications prior to and during vaccination.   No treatment medication details were reported.  Company comment:  This spontaneous case reported by a consumer, concerns a 18 year old male patient with no relevant medical history reported, who experienced the Unexpected, Serious (Medically significant) event of Cerebrovascular Accident (Stroke)(AESI ) and hemiparesis (Weakness on the entire right side of body for 20 minutes) about 5 months and 18 days after receiving the 2 dose of mRNA-1273 vaccine in the COVID-19 vaccination series, along with other non serious events. Patient had received the 1 dose with Moderna vaccine 28 days ago. On the next day of event onset, Magnetic resonance imaging revealed he had a Stroke.  No details on other comorbidities, risk factors, clinical course, labs, diagnostic tests, concomitant and treatment were provided. Hemiparesis had resolved and the event Cerebrovascular Accident had not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case reported by a consumer, concerns a 18 year old male patient with no relevant medical history reported, who experienced the Unexpected, Serious (Medically significant) event of Cerebrovascular Accident (Stroke)(AESI ) and hemiparesis (Weakness on the entire right side of body for 20 minutes) about 5 months and 18 days after receiving the 2 dose of mRNA-1273 vaccine in the COVID-19 vaccination series, along with other non serious events. Patient had received the 1 dose with Moderna vaccine 28 days ago. On the next day of event onset, Magnetic resonance imaging revealed he had a Stroke.  No details on other comorbidities, risk factors, clinical course, labs, diagnostic tests, concomitant and treatment were provided. Hemiparesis had resolved and the event Cerebrovascular Accident had not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.